Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$4.6 million.

  • Spyre Therapeutics' Cash from Financing Activities fell 13633.02% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.8 million, marking a year-over-year decrease of 3642.68%. This contributed to the annual value of $410.9 million for FY2024, which is 1380.01% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Cash from Financing Activities is -$4.6 million, which was down 13633.02% from $731000.0 recorded in Q2 2025.
  • Spyre Therapeutics' Cash from Financing Activities' 5-year high stood at $225.6 million during Q4 2024, with a 5-year trough of -$12.5 million in Q3 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was $360000.0 (2024), whereas its average is $42.8 million.
  • Over the last 5 years, Spyre Therapeutics' Cash from Financing Activities had its largest YoY gain of 204517500.0% in 2023, and its largest YoY loss of 953923.08% in 2023.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Cash from Financing Activities stood at $80000.0 in 2021, then plummeted by 110.0% to -$8000.0 in 2022, then skyrocketed by 2045175.0% to $163.6 million in 2023, then soared by 37.89% to $225.6 million in 2024, then tumbled by 102.06% to -$4.6 million in 2025.
  • Its Cash from Financing Activities stands at -$4.6 million for Q3 2025, versus $731000.0 for Q2 2025 and $125000.0 for Q1 2025.